Compare Amylx Pharmaceuticals Inc (AMLX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Norwegian Cruise Line Holdings Ltd trades at $19.46 (market cap $9.00B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4.5× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | NCLH | |
|---|---|---|
Market Cap | $1.98B | $9.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $26.94 |
52-Week Low | $7.64 | $14.79 |
Enterprise Value | $1.70B | $23.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Norwegian Cruise Line Holdings (NCLH) trades at $19.61, down 0.76% on the day, with technical indicators showing a neutral to bearish bias amid recent volatility. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 surpassing expectations of $0.15, while revenue reached $9.83 billion in 2025. Analyst sentiment remains largely positive with a consensus price target of $22.06, though high debt levels and macroeconomic sensitivities present ongoing risks.
NCLH offers potential upside based on earnings momentum and favorable valuation multiples, but investors face headwinds from elevated leverage and industry-specific volatility. The stock's near-term direction hinges on Q2 2026 earnings delivery and sustained travel demand amid fluctuating fuel costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
